Latest Breaking News On - Eisai co ltd - Page 1 : comparemela.com

FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Massachusetts
United-states
Tokyo
Japan
Brazil
Singapore
Switzerland
South-korea
Taiwan
Israel
Russia
China

FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb)

FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb)
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Israel
Massachusetts
United-states
Russia
Taiwan
Switzerland
Australia
Canada
Hong-kong
China
United-kingdom
Saudi-arabia

Bragar Eagel & Squire, P.C. Reminds Investors That Class

NEW YORK, June 09, 2024 (GLOBE NEWSWIRE) Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that.

United-states
New-york
Delaware
California
South-carolina
America
Kenneth-orr
Ronald-kisling
Bragar-eagel-squire
Todd-nightingale
Christophera-viehbacher
Marion-passmore

Biogen Inc.: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts

Tokyo
Japan
United-kingdom
Brazil
Hong-kong
Cambridge
Cambridgeshire
Taiwan
Russia
Switzerland
Israel
Massachusetts

FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Russia
Singapore
China
Switzerland
Taiwan
Israel
Canada
India
Japan
United-kingdom
Australia
Hong-kong